I'm a partner in the Intellectual Property Group based in London specialising in contentious patent matters with a particular focus and keen interest in the life sciences and healthcare sector.
Over the years, my particular expertise and focus has been developed through my involvement in and management of numerous commercially important, multi-jurisdictional and technically complex cases mainly in the field of pharmaceutical/biological patents for both innovator and generic clients up to the Supreme Court.
I have also built up complementary experience in advising and supporting our clients in a range of sectors in relation to their multi-jurisdictional patent portfolio management and strategy (including associated proceedings/enforcement and commercialisation), freedom to operate/validity and infringement analyses, specific regulatory considerations and IP due diligence and disclosure in corporate transactions.
I enjoy working in a team to develop strategy as well as getting into the detail of both technical and legal aspects. I have extensive experience collaborating with colleagues across our network as well as with other external advisors, technical experts and client personnel.
To assist in the effective collaboration, implementation and management of various projects, we work closely with clients in the development of e-tools and I have particular experience in tailoring our Access portal tool in the patent commercialisation context.
In recent years, I have also supported two multinational pharma clients on secondment in-house managing a heavy and diverse multi-jurisdictional workload spanning commercial, regulatory and IP litigation matters. This valuable experience has enabled me to gain a deeper understanding of the different business functions, the pharmaceutical regulatory regime and the varying public policy and health system issues which have become increasingly relevant to European patent/SPC litigation and strategy. I am also better placed to understand the pressures faced by our clients, the pragmatism needed to align legal and commercial objectives and what is most needed from an external adviser.
Last updated 29th June 2020